$IMUX

Immunic Inc (NASDAQ:IMUX) appointed Elena Ridloff to its board. Ridloff is CFO of Sionna Therapeutics and previously served as CFO at ACADIA Pharmaceuticals, where she helped raise $600 million. Immunic said the move supports progress toward late-stage milestones for vidofludimus calcium, including Phase 3 ENSURE top-line data expected by year-end.

IMMUNIC, INC. (IMUX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001280776 0001280776 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor

IMMUNIC, INC. (IMUX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 e665616_ex10-1.htm IMMUNIC, INC. 2019 OMNIBUS EQUITY INCENTIVE PLAN, AS AMENDED ON JUNE 28, 2023, MARCH 4, 2024, JUNE 4, 2025, AND JUNE 29, 2026 TABLE OF CONTENTS PAGE Article 1. Effective Date, Objectives and Duration 1 1.1 Effective Date of the Plan 1 1.2 Objectives o

Immunic (Nasdaq: IMUX) said it will present additional Phase 2 CALLIPER trial data on vidofludimus calcium (IMU-838) for progressive multiple sclerosis at the 2026 CMSC Annual Meeting. The late-breaking poster reports unified “confirmed disability change” analyses favoring vidofludimus vs placebo. Other posters cite similar safety vs placebo (TEAEs 69.4% vs 68.5%, discontinuations 2.6% each) and no worsening in PHQ-9 depressive thoughts through 120 weeks.

Immunic, Inc., a late-stage biotechnology company, has appointed Michael A. Panzara, M.D., M.P.H., as its new Chief Medical Officer, effective April 24, 2026. Dr. Panzara brings over 25 years of neurology experience and will lead the company's development organization, including clinical and regulatory affairs, with a focus on advancing vidofludimus calcium through pivotal trials for multiple sclerosis. This appointment marks a critical step for Immunic as it transitions towards becoming a fully integrated commercial-stage company.

Immunic, Inc. has appointed Jon Congleton to its board of directors, effective March 27, leveraging his nearly 40 years of biopharmaceutical experience, particularly in central nervous system and multiple sclerosis treatments. Congleton, who helped launch Copaxone, currently serves as CEO of Mineralys Therapeutics and previously held CEO roles at Impel NeuroPharma and Nivalis Therapeutics. The biotechnology company is developing oral therapies for neurologic diseases, with its lead program in Phase 3 clinical trials, and has recently secured a $200 million private placement financing.

Immunic Inc's (IMUX) short interest has decreased by 7.19% since its last report, now standing at 6.57 million shares sold short, which is 5.55% of its float. This decline suggests a more bullish sentiment among investors compared to the previous report. The company's short interest is also lower than its peer group average of 10.21%.

D. Boral Capital has lowered its price target for Immunic (IMUX) from $8.00 to $4.00, representing a 50% decrease, while maintaining a 'Buy' rating. This adjustment reflects a shift in future performance expectations for the clinical-stage biopharmaceutical company despite ongoing positive long-term outlooks from analysts. The average target price from 8 analysts is $5.38, suggesting a significant upside from its current price, and the consensus recommendation is "Outperform."

Immunic Inc. announced a private placement aiming to raise up to $400 million to finance the late-stage development of its multiple sclerosis pipeline and support its transition into a commercial-stage company. The funding will largely go towards completing Phase 3 trials for vidofludimus calcium and expanding preparatory commercial infrastructure. Concurrently, Immunic is undergoing leadership changes, with its co-founder and CEO Daniel Vitt moving to a senior executive role focusing on scientific strategy as the company seeks a new CEO with commercial MS experience.